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Background: Ataxia Telangiectasia Mutated (ATM) serine/threonine protein kinase
is a known tumor suppressor, involved in DNA damage repair. It has prognostic and
predictive therapeutic implications and is associated with aggressive prostate
cancer (PCa).
Objective: To investigate the prognostic value of ATM protein expression in PCa
patients and assessed the combined value of ATM, ERG, and PTEN status.
Design, setting, and participants: This study consisted of 303 patients with incidental, locally advanced, and castrate-resistant PCa by transurethral resection of
the prostate (TURP).
Outcome measurements and statistical analysis: TURP samples from 303 PCa
patients were assessed by immunohistochemistry (IHC for ATM, ERG, and PTEN.
Individual and combined marker status were correlated with International Society
of Urological Pathology Gleason grade group, overall survival (OS), and PCa-speciﬁc
mortality (PCSM).
Results and limitations: Decreased ATM expression (negative/weak intensity)
occurred in 164/303 (54.1%) patients, and was associated with shorter OS and
higher PCSM (p = 0.015 and p = 0.001, respectively). Negative/weak ATM expression was signiﬁcantly associated with PCSM with a hazard ratio of 2.09 (95%
conﬁdence interval 1.34–3.27, p = 0.001). Assessment of Combined ATM/PTEN
expression showed improved prognostic power to predict OS and PCSM, independent of Gleason grade groups.
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Conclusions: Decreased ATM protein expression is associated with poor outcomes
in advanced PCa patients. Patients with combined low ATM/PTEN negative expression are at the highest risk for reduced OS and PCSM. Assessing the combined status
of ATM/PTEN by IHC in PCa patients may aid in risk stratiﬁcation relative to OS and
PCSM. Moreover, since ATM plays an integral role in DNA damage response pathways, future studies will enhance our understanding of how outcomes of patients
with altered ATM and PTEN expression can be improved further with poly-ADP
ribose polymerase inhibitors (PARPi), combinations of PARPi and androgen
receptor–targeted therapies, as well as platinum-based chemotherapies.
Patient summary: Lower ATM intensity is associated with increased cancer-speciﬁc mortality in prostate cancer patients. Patients with lower ATM and PTEN
negative expression showed decreased overall survival and increased cancer
mortality compared with controls.
© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1.

Introduction

Prostate cancer (PCa) is among the top cancers facing men
in the western world. Despite our enhanced understanding
of DNA damage repair (DDR) alterations in PCa, there
continues to be a great need for biomarkers that are more
effective at predicting outcomes and treatment responses,
particularly in advanced disease. However, there is great
heterogeneity in the DDR group, where data are largely
driven by BRCA2 alterations, as exemplified by the gene-bygene subgroup analysis of the PROFOUND clinical trial
[1]. To date, there is a need to develop biomarkers that could
more easily be implemented clinically to predict which
patients are likely to benefit from targeted therapy (eg,
poly-ADP ribose polymerase inhibitors [PARPi]) or platinum-based chemotherapy, while assisting in stratification
of patients into different prognostic groups.
Germline and somatic mutations in the DNA repair and
DDR pathways have gained increasing attention in PCa [2–
7]. Recent data suggest that 23% of metastatic castrateresistant patients will harbor germline or somatic DDR
variants, with germline variants occurring in approximately
12% of patients with metastatic castrate-resistant prostate
cancer (mCRPC) [8,9]. The most commonly mutated DDR
gene in PCa is BRCA2 [8]. The Ataxia Telangiectasia Mutated
serine/threonine kinase (ATM) gene, which is located on
11q22.3, is required for DDR pathway signaling, and
mutations in this gene are present in roughly 6% of mCRPC
patients [2,10]. However, loss of ATM protein expression as
detected by immunohistochemistry (IHC) far exceeds the
above rate of ATM mutations in lung adenocarcinoma
[11]. This may be due to epigenetic changes such as
methylation of the ATM gene [12]. All these data, along with
our recent report documenting that ATM-deficient cancer
cell lines are sensitive to the combination of PARPi plus an
ATR inhibitor but not to either agent alone [2,4–7], indicate
that an assessment of patients’ tumor samples for decreased
activity by IHC may allow for better identification of
patients who could benefit from combination targeted
therapies.

Patients with mCRPC harboring ATM, BRCA2, or BRCA1
mutations have experienced overall survival (OS) and
radiographic progression-free survival (rPFS) benefit when
treated with PARP inhibition (olaparib), in contrast to
patients with physician’s choice androgen receptor (AR)targeted therapy [1]. In an exploratory gene-by-gene
subgroup analysis, patients with ATM alterations seemed
to derive a somewhat lower rPFS benefit than previously
expected [1]. It is necessary to clearly define the specific
clinical outcomes associated with altered ATM protein
expression in PCa.
ERG expression reflective of TMPRSS2-ERG gene rearrangements is known to play a significant role in PCa subtyping,
being detected in close to 50% of cases. PTEN deletions are
also known to be a significant player in PCa progression, and
its incidence is increased with higher grade group (GG) and
stage, and in castration-resistant disease.
Given the importance of ERG and PTEN genomic
alteration as a significant player in PCa subtyping and
prognosis, we aimed to incorporate the prognostic value
and association of ATM status combined with ERG and PTEN
status. In this study, we investigated the prognostic value of
ATM protein expression in a cohort of PCa patients treated
mainly by androgen deprivation therapy (ADT) and assessed
the combined value of ATM, ERG, and PTEN IHC status in
relation to lethal disease and OS [13,14].
2.

Patients and methods

2.1.

Study population and tissue microarray construction

The study cohort consisted of men diagnosed with PCa by transurethral
resection of the prostate (TURP) between 2005 and 2013 (n = 303).
Patients within this cohort were either not treated actively or treated by
luteinizing hormone-releasing hormone (LHRH) agonist, and spanned
from incidental, locally advanced disease to metastatic castrate-resistant
disease. Treatments were implemented after TURP (advanced group) or
prior to TURP samples in patients who had a previous diagnosis of PCa to
relieve symptomatic obstruction of locally advanced disease while on
LHRH (castrate-resistant prostate cancer [CRPC] group). The incidental
group was deﬁned as the group of patients with no prior hormonal
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therapy with Gleason GG of 3. Those with Gleason GG 4 without prior

TMAs for analysis. Figures 1 and 2 show examples of ATM intensity in

hormonal therapy were considered the advanced group. Clinical follow-

various Gleason GGs.

up information was recorded and approved by the University of Calgary
and Cumming School of Medicine ethics review board from the Alberta

2.4.

Statistical analysis

Tumour Registry for dates of therapy, survival, and cause-speciﬁc
survival. The cohort’s samples were assembled onto two tissue

SPSS version 25 was used to conduct all statistical analysis (IBM SPSS

microarrays (TMAs) with an average of two cores per patient using a

Statistics for Windows, version 25.0, released 2017; IBM Corp.,

manual tissue arrayer (Beecher Instruments, Silver Spring, MD, USA).

Armonk, NY, USA). Frequency and proportions were reported for

Adjacent benign prostate tissue samples were also available for analysis.

categorical data. Mean and standard deviations were reported for

However, benign samples analysis was limited in number as the TMA

normally distributed continuous data; median and range were

was constructed mainly from tumor areas (n = 135). The proportions of

reported for non-normally distributed continuous data. Chi-square

benign tissues analyzed were 46 (55.4%) in the incidental, 21 (25.3%) in

tests were used to compare two categorical variables, and Fisher’s

the advanced, and 12 (14.4%) in the castrate-resistant group.

exact test was used where the cell frequencies were <5. OS was

2.2.

TURP specimen to the date of death; patients alive at the end of the

deﬁned as the time from the date of diagnosis of PCa as detected on

ATM, ERG, and PTEN expression by IHC

study period were censored. Prostate cancer–speciﬁc mortality (PCSM)
ATM IHC was performed on a Dako Omnis autostainer. Brieﬂy, 4

mm

was deﬁned as death due to PCa; patients who died due to other reason

formalin-ﬁxed parafﬁn-embedded sections were pretreated with citrate

or who were alive at the end of the study period were censored. OS,

pH 9.0 epitope retrieval buffer. We used a rabbit monoclonal to

PCSM, and recurrence-free survival (RFS) were analyzed using the

recombinant ATM (Y170 from Abcam #32420). The antibody was used

Kaplan-Meier method. Median time and the 95% conﬁdence interval

diluted to 1/400 using Dako antibody diluent and incubated for 30 min,

(CI) were reported. Log rank tests were used to compare two or more

followed by 30 min secondary incubation. The FLEX DAB+ Substrate

survival curves. Cox proportional hazards models were used to

Chromogen system was used as a postincubation detection reagent. ATM

determine the factors associated with OS, PCSM, and RFS; the hazard

HC expression was assessed using a four-tiered system (0, negative; 1,

ratio (HR) and the corresponding 95% CI were reported. Adjusted Cox

weak; 2, moderate; and 3, high intensity) relative to internal control of

model was ﬁtted as well. A p value of <0.05 was used for statistical

stromal and basal cells. ERG and PTEN IHC was assessed as negative

signiﬁcance, and two-sided tests were used.

versus positive and stained as previously described [14,15].

2.3.

Pathological analysis

Histological diagnoses of individual TMA cores were conﬁrmed by the
study pathologists (S.W., R.S., and T.A.B.) on the initial slides. Gleason
scoring was assessed according to the 2014 World Health Organization/
International Society of Urological Pathology GGs. In each patient, the
predominant two patterns of PCa were sampled and included on the

3.

Results

3.1.

ATM protein expression across various PCa stages and in

relation to Gleason GGs and other genomic aberrations

A total of 303 cancer samples were analyzed with
135 adjacent benign samples. Decreased ATM intensity in

Fig. 1 – Examples of ATM intensity in benign prostate tissue and various prostate cancer grade groups: (A) benign prostate tissue showing high ATM
intensity similar to high internal control (stromal and basal cells),(B) Gleason grade group 1 showing high intensity similar to internal control, (C)
ductal type prostate cancer showing negative ATM intensity (note positive internal control cells), (D) Gleason grade group 5 showing weak ATM
intensity compared with high positive control, and (E) Gleason grade group 5 showing high intensity. (F) Error bars for mean intensity values of ATM
across various stages of prostate cancer progression. CRPC = castrate-resistant prostate cancer.
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Fig. 2 – Higher magnification of ATM expression relative to internal control: (A) high ATM intensity similar to internal control, (B) moderate ATM
intensity slightly lower than internal control, (C) weak ATM intensity relative to internal control, and (D) negative ATM intensity relative to positive
control.

PCa was noted in 164/303 (54.1%) patients. Table 1 lists the
distribution of the subgroups included, and their median
follow-up and OS/cause-specific survival. Table 2 lists
patients’ demographics and biomarker distributions within
the cohort studied. ATM intensity was comparable between
PCa diagnosis and benign prostate tissue (mean = 1.06,
standard
deviation
[SD] = 0.903
vs
mean = 1.07,
SD = 0.903; p = 0.9608). ATM intensity was also significantly lower in CRPC and advanced PCa than in incidental
disease (1.15  0.87 and 1.13  0.0.88 vs 1.59  0.90,
p < 0.0001; Fig. 1F).
Decreased ATM was also associated with advanced
Gleason grade grouping, with 87/125 (57.2%) patients with
GG5 showing decreased ATM expression versus 38/97 (25%)
of GG1 (p < 0.0001). Although, no significant association
was observed between ATM intensity and that of PTEN or
ERG, 20.1% (61/303) patients showed decreased ATM
intensity and loss of PTEN expression. On the contrary,
38.6% (117/303) patients in this cohort showed combined
ERG negative and decreased ATM intensity.

3.2.

Association of ATM with patients’ clinical outcome

Decreased ATM intensity (negative/weak; suggested to be
referenced as high risk) was associated with poor OS and
cancer-specific mortality (HR: 1.45; CI: 1.08–1.96, p = 0.015,
and HR: 2.09; CI: 1.34–3.27, p = 0.001, respectively; Fig. 3A
and B), in contrast to patients with normal ATM intensity
(moderate/high; suggested to be referenced as low risk).
The median OS for low-risk ATM was 59.4 (54.3–64.6) mo
and that for high-risk ATM was 38.7 (31.0–46.4) mo. The
median PCSM values for low- and high-risk ATM were,
respectively, 85.3 and 64.0 mo (43.9–84.1; p = 0.014 and
0.001, respectively). However, the associations reported
between ATM expression and OS or PCSM was not
significant after adjusting for Gleason score.
Since PTEN and ERG are known to be significantly
associated with disease progression and patient prognosis,
we opted to investigate whether combining ATM intensity
with PTEN or ERG intensity would provide added prognostic
value. In this cohort, patients’ tumors with low ATM
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Table 1 – Patients’ subgroup distribution within the TURP cohort
Group

N (%)

Overall survival

Median
follow-up (mo)

Median
OS (mo)

p value

a

Total N (events)
Incidental
108 (35.6) 104 (42)
114 (37.6) 109 (76)
Advanced
Castrate resistant 81 (26.7) 78 (65)
Overall

PCSM

Median
PCSM (mo)

p value

a

Total N (events)
50.96 (7.785–101.22)
37.91 (1.48–99.09)
20.58 (1.54–93.77)
38.74 (1.48–101.22)

73.92 (63.26–84.58) <0.0001
41.82 (28.69–54.95)
20.63 (9.71–31.56)
45.50 (37.47–53.54)

104 (2)
109 (42)
78 (48)

Not reached
<0.0001
66.43 (51.39–81.48)
33.87 (22.63–45.11)
Not reached

CRPC = castrate-resistant prostate cancer; LHRH = luteinizing hormone-releasing hormone; OS = overall survival; PCa = prostate cancer; PCSM = prostate
cancer–speciﬁc mortality; TURP = transurethral resection of the prostate.
Incidental group: patients with no prior hormonal therapy with Gleason grade group of 3; advanced group: patients with Gleason grade group 4 without
prior hormonal therapy or patients with posthormonal therapy; castrate-resistant group: patients with previous diagnosis of PCa who underwent TURP to
relieve symptomatic obstruction of locally advanced disease while on LHRH (CRPC group).
a
Log-rank p values.

Table 2 – Patients’ demographics and biomarker distribution
(n=303)
Variables

a

Gleason score
Grade group 1
Grade group 2 (3 + 4)
Grade group 3 (4 + 3)
Grade group 4 (8)
Grade group 5 (9/10)
Missing
Deceased
Yes
No
Missing
Prostate cancer–speciﬁc mortality
Yes
No
Cancer subgroup
Incidental
Advanced
Castrate resistant
ATM score (score by cancer subgroup)
Score 0/1
Incidental score 0/1
Advanced score 0/1
Castrate-resistant score 0/1
Score 2/3
Incidental score 2/3
Advanced score 2/3
Castrate-resistant score 2/3
PTEN and ATM combined
PTEN negative and ATM score 0/1
PTEN negative and ATM score 2/3
PTEN positive and ATM score 0/1
PTEN positive and ATM score 2/3
Missing
ERG and ATM combined
ERG positive and ATM score 0/1
ERG positive and ATM score 2/3
ERG negative and ATM score 0/1
ERG negative and ATM score 2/3
Missing

Total (n = 303), n (%)

97 (32.0)
28 (9.2)
18 (5.9)
21 (6.9)
125 (41.3)
14 (4.6)
183 (60.4)
118 (38.9)
12 (0.7)
92 (30.4)
211 (69.6)
108 (35.6)
114 (37.6)
81 (26.7)
164 (54.1)
38 (12.5)
76 (25.1)
50 (16.5)
139 (45.9)
70 (23.1)
38 (12.5)
31 (10.2)
61 (20.1)
41 (13.5)
94 (31.0)
84 (27.7)
23 (7.6)
38 (12.5)
38 (12.5)
117 (38.6)
87 (28.7)
23 (7.6)

a

ATM scores: 0, negative; 1, weak; 2, moderate; and 3, high. PTEN/ERG
positive refers to any intensity.

intensity and PTEN negative staining or negative ERG
expression were associated with significantly lower OS and
higher cancer-specific mortality, compared with patients
with other combinations of ATM and PTEN. The prognostic

value of combined ATM/PTEN or ATM/ERG status was
higher than that of ATM, PTEN, or ERG alone. Patients with
decreased ATM expression and PTEN negative expression
showed the highest association with lethal disease (Table 3).
However, after adjusting for Gleason GG, the combined
ATM/PTEN signature was the only combination significant
to PCSM and OS (HR: 2.58, CI: 1.23–5.39, p = 0.012, and HR:
1.81, CI: 1.13–2.9, p = 0.0145, respectively; Fig. 4A and B, and
Table 4). Again, there was significant disadvantage for OS
and PCSM between the low- and high-risk groups for
combined PTEN/ATM status. For PTEN loss and high-risk
ATM, median OS was 20.6 (14.4–26.8) mo, in contrast to the
PTEN intact and low-risk ATM median OS of 65.2 (57.5–72.8)
mo (p < 0.0001). For PCSM, PTEN loss and high-risk ATM
mean PCSM was 36.4 (23.2–49.6) mo versus PTEN intact and
low-risk ATM mean PCSM of 85.3 (58.7–111.8) mo (p < 0.0001). To gain additional insight into the prognostication of ATM/PTEN status, we investigated the prognostic
value of combined PTEN/ATM status and ERG/ATM adjusting for metastatic disease at presentation. As shown in
Table 5, the most powerful combination for OS and PCSM
was PTEN negative/ATM high risk (ie, negative to weak
intensity) with HRs of 2.47 (95% CI: 1.60–3.83, p < 0.001)
and 3.92 (95% CI: 2.02–7.62, p < 0.0001), respectively. The
combination of ERG, PTEN, and ATM for OS demonstrated an
HR of 1.47 (0.95–2.27, p = 0.081). When adjusting this HR for
Gleason score, the HR is 0.96 (0.60–1.54, p = 0.871). For
PCSM, the combination of ERG, PTEN, and ATM gave HRs of
2.09 (1.34–3.27, p = 0.001), and an HR of 0.91 (0.48–1.73,
p = 0.768) was obtained when adjusting HR for Gleason
score.
4.

Discussion

In this study, we document significant prognostic value for
ATM protein expression in patients with advanced PCa.
Patients with decreased ATM expression were more likely to
exhibit lethal outcome with HRs of about 1.5 times.
Incorporation of the status of PTEN into ATM showed an
even higher association with lethal disease, with almost
three-fold that of the control group, and even after adjusting
for Gleason GG, this was still significant at about 1.5 times
the risk for lethal disease. Incorporation of validated
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Fig. 3 – Kaplan-Meier curves for ATM expression relative to (A) overall survival and (B) prostate cancer–specific mortality. ATM intensity: negative/weak
versus moderate/high.

Table 3 – Univariate analysis for overall survival and cancer-specific mortality
Variables

a

Overall survival
HR (95% CI)

ATM score 2/3
score 0/1
PTEN and ATM combined (PTEN positive and ATM score 2/3)
PTEN negative and ATM score 0/1
PTEN negative and ATM score 2/3
PTEN positive and ATM score 0/1
ERG and ATM combined (ERG negative and ATM score 2/3)
ERG positive and ATM score 0/1
ERG positive and ATM score 2/3
ERG negative and ATM score 0/1

Prostate cancer–speciﬁc mortality
p value

HR (95% CI)

p value

1.45 (1.08–1.96)

0.015

2.09 (1.34–3.27)

0.001

2.88 (1.89–4.40)
2.13 (1.31–3.47)
1.33 (0.88–2.02)

<0.0001
0.002
0.177

5.31 (2.80–10.09)
3.19 (1.52–6.71)
2.03 (1.05–3.90)

<0.0001
0.002
0.034

2.18(1.37–3.48)
1.79(1.09–2.94)
1.51(1.03–2.21)

0.001
0.022
0.033

3.24(1.61–6.49)
2.51(1.19–5.27)
2.50(1.40–4.47)

0.001
0.015
0.002

CI = conﬁdence interval; HR = hazard ratio.
ATM scores: 0, negative; 1, weak; 2, moderate; and 3, high. PTEN/ERG positive refers to any intensity.

a

biomarkers into clinical practice would be of great
importance in improving our predictability of disease
progression. This would allow for better targeted therapy
validation for those at the highest risk of disease progression. Furthermore, as more men with low- and intermediate-grade PCa elect to enroll into active surveillance
programs versus active therapy, such biomarkers that are
easily implemented clinically at a fractional cost of those for
complex genomic signatures may prove to be easier to be
incorporated into clinical practice [16]. Therefore, considerable research is conducted to improve clinical insights
and assist in the development of precision therapies for
advanced PCa [16,17]. Several reports showed a significant
correlation between ERG rearrangements and PTEN deletions in PCa [14,17,18]. ERG and PTEN genomic aberrations
have been shown to be prevalent (up to 40% and 50%,
respectively) in PCa, and both aberrations have been

suggested to inform about distinct molecular subtypes of
PCa in addition to other key genomic markers such as SPOP
and SPINK1 genomic aberrations [19,20].
A major benefit of our study is that we carried out a
detailed investigation about the prognostic value of
assessing ATM protein expression in a large cohort of
men with PCa. Additionally, we associated ATM expression
with PTEN and ERG expression, and confirmed added
prognostic value for assessing ATM and PTEN intensity in
men with PCa in relation to cause-specific mortality and OS.
Establishment of conditions for IHC of ATM protein
expression in PCa patients as described here may also be
beneficial in selection of patients who might benefit from
treatment with a PARPi combined with an ATR inhibitor, as
shown in our in vitro studies [2,4]; however, the effects of
loss of ERG and/or PTEN on sensitivity of ATM-deficient PCa
cells to PARPi and ATR inhibitors remains to be determined.
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Fig. 4 – Kaplan-Meier curves for combined ATM and PTEN expression relative to (A) overall survival and (A) prostate cancer–specific mortality. ATM
negative/weak versus moderate/high, and PTEN negative versus PTEN expression.

Table 4 – Multivariate analysis and HRs of the different biomarker combinations for overall survival and prostate cancer–specific mortality
in the TURP cohort (multivariate analysis for overall and cause-specific survival a)
Variables

b

Overall survival

HR (95% CI)
PTEN and ATM combined (PTEN positive and ATM score 2/3
PTEN negative and ATM score 0/1
PTEN negative and ATM score 2/3
PTEN positive and ATM score 0/1
ERG and ATM combined (ERG negative and ATM score 2/3)
ERG positive and ATM score 0/1
ERG positive and ATM score 2/3
ERG negative and ATM score 0/1

Prostate cancer–speciﬁc
mortality
p value

HR (95% CI)

p value

1.81(1.13–2.9)
1.66(0.99–2.78)
1.18(0.76–1.83)

0.0145
0.054
0.454

2.58(1.23–5.39)
2.15(0.93–4.93)
1.74(0.84–3.60)

0.012
0.072
0.135

1.35(0.81–2.25)
1.44(0.85–2.43)
1.28(0.85–1.92)

0.248
0.173
0.239

1.54(0.69–3.45)
1.91(0.83–4.36)
2.08(1.06–4.06)

0.290
0.127
0.033

CI = conﬁdence interval; HR = hazard ratio; TURP = transurethral resection of the prostate.
Adjusted for Gleason score.
b
ATM scores: 0, negative; 1, weak; 2, moderate; and 3, high. PTEN/ERG positive refers to any intensity.
a

Table 5 – Multivariate analysis and HRs of the different biomarker combinations for overall survival and cancer-specific mortality in the
TURP cohort (adjusted for metastatic disease at the time of presentation)
Variables

a

PTEN and ATM combined (PTEN positive and ATM score 2/3
PTEN negative and ATM score 0/1
PTEN negative and ATM score 2/3
PTEN positive and ATM score 0/1
ERG and ATM combined (ERG negative and ATM score 2/3)
ERG positive and ATM score 0/1
ERG positive and ATM score 2/3
ERG negative and ATM score 0/1

Overall survival

Prostate cancer–speciﬁc
mortality

HR (95% CI)

p value

HR (95% CI)

p value

2.47(1.60–3.83)
1.85(1.13–3.02)
1.28(0.84–1.94)

<0.0001
0.015
0.251

3.92(2.02–7.62)
2.77(1.32–5.84)
1.85(0.96–3.57)

<0.0001
0.007
0.066

1.87(1.16–3.01)
1.48(0.89–2.45)
1.39(0.94–2.03)

0.010
0.131
0.097

2.38(1.17–4.86)
2.03(0.96–4.30)
2.10(1.16–3.79)

0.017
0.063
0.014

CI = conﬁdence interval; HR = hazard ratio; TURP = transurethral resection of the prostate.
ATM scores: 0, negative; 1, weak; 2, moderate; and 3, high-intensity staining. PTEN/ERG positive refers to any intensity.
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In the current study, assessment of the combination of
ATM/PTEN status showed significant differences in OS and
PCSM between high- and low-risk groups as pertaining to
PTEN/ATM intensities. Patients with tumors showing both
low ATM expression and loss of PTEN expression (high-risk
group) demonstrated significantly poorer OS and PCSM of
close to 3.3 and 4.07 yr, respectively, compared with patients
in the low-risk group for PTEN/ATM. The latter data support
potentially incorporating the combined status of ATM/PTEN
to assist in better stratifying PCa patients and identify those at
a higher risk for lethal outcome and potential benefit from
ADT. Additionally, since an exploratory gene level subgroup
analysis of the OS PROFOUND data suggests that patients
with ATM alterations, in contrast to other homologous
recombination repair alterations, may derive less benefit
with olaparib PARPi, this may be a more elegant predictive
biomarker to determine which patients with ATM alterations
may benefit from PARPi and show OS and PCSM survival
advantage [1]. Future studies will enhance our understanding
of how outcomes of patients with altered ATM and PTEN
expression can be enhanced further with PARPi, combinations of PARPi and AR-targeted therapies, as well as platinumbased chemotherapies [21,22].
Our study had several limitations. Unfortunately, we had
incomplete data for Gleason scoring, survival/death, and
ATM IHC status. Our study was a retrospective study and
lacked an independent cohort of validation. Furthermore,
we did not have access to TNM staging information for our
cohort.
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